Theorem Clinical Research Expands its Cardiovascular Expertise Through Alliance With BioTelemetry
Theorem Clinical Research has announced the formation of a strategic alliance with BioTelemetry, Inc.
Theorem Clinical Research
, a clinical research organization specializing in complex trials, has announced the formation of a strategic alliance with BioTelemetry, Inc. (Nasdaq: BEAT). BioTelemetry’s Clinical Research division includes Cardiocore, a global cardiac core laboratory.
“Theorem’s business strategy is to offer our clients the very best in every service area,” said
John Potthoff
, Theorem president and CEO. “BioTelemetry reinforces that strategy with a team of industry-leading scientists, a set of advanced technologies and a broad base of cardiac testing modalities. Theorem clients will benefit from BioTelemetry’s expert consulting services and deep experience across all major therapeutic areas.”
BioTelemetry
CEO Joseph Capper noted, “Theorem’s experience in complex protocols aligns perfectly with our specialized cardiovascular testing services. The partnership complements BioTelemetry’s unique position that spans from clinical research through post-market surveillance and into clinical practice. Both companies support trials in
all clinical phases
of pharmaceutical and biotech development and will collaborate globally within this alliance.”
“Trends in the industry such as safety monitoring boards, translational medicine and risk-based monitoring put additional pressures on the clinical trial process to be faster, safer and more efficient,” said Potthoff. “Our strategic partnership with BioTelemetry allows us to meet — and exceed — those industry standards for our clients.”
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.
